Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
$0.79
-21.7%
$6.76
$2.06
$7.01
$110.80M1.598.44 million shs1,910 shs
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$12.44
-1.0%
$12.81
$9.40
$15.96
$503.82M0.75141,333 shs122,344 shs
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
$1.03
$1.01
$0.32
$1.57
$211.41M2.151.93 million shsN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.87
-2.6%
$2.23
$1.86
$4.73
$21.56M1.0321,127 shs10,587 shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
0.00%0.00%0.00%0.00%+349.54%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
-7.71%-2.41%+0.08%+12.14%-18.49%
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.00%0.00%0.00%0.00%+12.45%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
+1.59%+1.59%-16.16%-16.52%-46.81%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
4.4988 of 5 stars
2.04.02.51.13.73.32.5
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
N/AN/AN/AN/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
2.00
Hold$15.3323.26% Upside
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
2.00
HoldN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
2.00
HoldN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
N/AN/AN/AN/A$1.92 per shareN/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$977.90M0.52$1.89 per share6.58$6.97 per share1.78
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
$10.11M20.91N/AN/A$0.15 per share6.87
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.30M16.59N/AN/A$2.77 per share0.68

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
-$70.27M-$0.51N/AN/AN/AN/A-30.95%-29.09%N/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$32.61M$0.3634.5610.285.021.51%16.67%4.73%5/8/2024 (Confirmed)
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-$10.28MN/A0.00N/AN/A-25.54%-14.87%5/20/2024 (Estimated)

Latest SPPI, PAHC, ACHN, and TXMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.29N/A-$0.29N/AN/AN/A  
2/7/2024Q2 2024
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.27$0.33+$0.06$0.63$242.91 million$249.90 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
N/AN/AN/AN/AN/A
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
$0.483.86%N/A133.33%N/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/A

Latest SPPI, PAHC, ACHN, and TXMD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/6/2024
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
Quarterly$0.124.5%3/5/20243/6/20243/27/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
0.01
8.96
8.96
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1.66
3.12
1.60
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/A
2.71
2.38
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A
1.72
1.72

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
79.42%
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
99.34%
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
21.67%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
30.74%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
56140.05 millionN/AOptionable
Phibro Animal Health Co. stock logo
PAHC
Phibro Animal Health
1,92040.50 million20.23 millionOptionable
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
86205.25 million199.70 millionOptionable
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
111.53 million11.39 millionOptionable

SPPI, PAHC, ACHN, and TXMD Headlines

SourceHeadline
TherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.comTherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.com
americanbankingnews.com - April 25 at 2:52 AM
TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.comTherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com
americanbankingnews.com - April 19 at 2:14 AM
TherapeuticsMD gets grant for progesterone formulation for oral administration with reduced dosageTherapeuticsMD gets grant for progesterone formulation for oral administration with reduced dosage
pharmaceutical-technology.com - April 18 at 9:36 AM
TherapeuticsMD Announces Full Year 2023 Financial ResultsTherapeuticsMD Announces Full Year 2023 Financial Results
businesswire.com - March 29 at 4:00 PM
TherapeuticsMD gets grant for progesterone formulations with reduced dosage for oral administrationTherapeuticsMD gets grant for progesterone formulations with reduced dosage for oral administration
pharmaceutical-technology.com - March 28 at 11:17 AM
25 Countries With Highest Abortion Rates25 Countries With Highest Abortion Rates
msn.com - March 12 at 3:55 PM
TherapeuticsMD, Inc. (TXMD) stock historical prices & data – Yahoo FinanceTherapeuticsMD, Inc. (TXMD) stock historical prices & data – Yahoo Finance
sg.finance.yahoo.com - March 10 at 1:13 PM
TherapeuticsMD Inc TXMDTherapeuticsMD Inc TXMD
morningstar.com - December 29 at 5:48 PM
Daily Markets: Today Brings Producer Prices, Retail Sales DataDaily Markets: Today Brings Producer Prices, Retail Sales Data
nasdaq.com - November 15 at 9:54 AM
TherapeuticsMD to Consider Strategic AlternativesTherapeuticsMD to Consider Strategic Alternatives
marketwatch.com - November 14 at 7:04 PM
TherapeuticsMD exploring strategic alternatives for companyTherapeuticsMD exploring strategic alternatives for company
msn.com - November 14 at 6:27 PM
TherapeuticsMD Announces Third Quarter 2023 Financial ResultsTherapeuticsMD Announces Third Quarter 2023 Financial Results
finance.yahoo.com - November 14 at 6:27 PM
Boca Raton-based prescription service announces layoffs, says a third of workforce could be cutBoca Raton-based prescription service announces layoffs, says a third of workforce could be cut
bizjournals.com - October 4 at 5:11 PM
TherapeuticsMD Inc. stock falls Wednesday, underperforms marketTherapeuticsMD Inc. stock falls Wednesday, underperforms market
marketwatch.com - September 20 at 6:46 PM
TherapeuticsMD Inc. stock outperforms market despite losses on the dayTherapeuticsMD Inc. stock outperforms market despite losses on the day
marketwatch.com - August 15 at 7:00 PM
TherapeuticsMD Announces Second Quarter 2023 Financial ResultsTherapeuticsMD Announces Second Quarter 2023 Financial Results
finance.yahoo.com - August 14 at 7:50 AM
Micron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of DirectorsMicron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of Directors
finance.yahoo.com - August 9 at 8:38 PM
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitorsTherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors
marketwatch.com - July 5 at 6:51 PM
TherapeuticsMD Rejected by FDA, Delay Could Be FatalTherapeuticsMD Rejected by FDA, Delay Could Be Fatal
thestreet.com - July 4 at 7:28 AM
TherapeuticsMD Inc. [TXMD] Investment Appeal on the RiseTherapeuticsMD Inc. [TXMD] Investment Appeal on the Rise
knoxdaily.com - June 19 at 3:12 PM
TherapeuticsMD: From Fallen And Forgotten To Cash CowTherapeuticsMD: From Fallen And Forgotten To Cash Cow
seekingalpha.com - May 23 at 9:28 AM
TherapeuticsMD Announces First Quarter 2023 Financial ResultsTherapeuticsMD Announces First Quarter 2023 Financial Results
finance.yahoo.com - May 15 at 4:19 PM
NeuroBo Pharmaceuticals (NRBO) Appoints Mark A. Glickman to its ... - StreetInsider.comNeuroBo Pharmaceuticals (NRBO) Appoints Mark A. Glickman to its ... - StreetInsider.com
news.google.com - May 14 at 10:42 AM
NeuroBo Pharmaceuticals Appoints Mark A. Glickman to its Board of ... - citybizNeuroBo Pharmaceuticals Appoints Mark A. Glickman to its Board of ... - citybiz
news.google.com - May 13 at 7:51 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Achillion Pharmaceuticals logo

Achillion Pharmaceuticals

NASDAQ:ACHN
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.
Phibro Animal Health logo

Phibro Animal Health

NASDAQ:PAHC
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, industrial, environmental, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
Spectrum Pharmaceuticals logo

Spectrum Pharmaceuticals

NASDAQ:SPPI
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.
TherapeuticsMD logo

TherapeuticsMD

NASDAQ:TXMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.